| |
With three foreign trade zones, including the largest non-contiguous zone in the U.S., bioscience firms in Puerto Rico profit from affordable international trade. It's not what's next, it's where. Puerto Rico. .png)
|
|
Today’s Big NewsMay 7, 2024 |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
| By Angus Liu With $1.1 billion cash on Madrigal Pharmaceuticals’ balance sheet, CEO Bill Sibold believes the company can “fully resource” the launch of Rezdiffra, the first FDA-approved therapy for fatty liver disease. |
|
|
|
By Annalee Armstrong Mark your calendars: Eli Lilly will come before the FDA’s advisory committee to discuss Alzheimer’s disease medicine donanemab June 10. |
By Annalee Armstrong Fierce 15 is here! Nominations are open now in search of the best and brightest in biotech. |
By Fraiser Kansteiner As of mid-April, Vertex said it had collected 5 patients' cells for eventual treatment with sickle cell disease therapy Casgevy. That puts Vertex ahead of its gene therapy rival bluebird bio, which recently said it had collected just one patient's cells for its own SCD treatment Lyfgenia. |
|
Tuesday, May 16, 2024 | 10 ET / 7am PT Clinical trials are shifting towards sustainability and efficiency, necessitating industry leaders to embrace innovative provisioned device solutions. This webinar reveals new approaches reshaping the clinical trial supply chain to mitigate carbon footprints and revolutionize device lifecycle management. Explore how proactive sustainability in device management can differentiate leading companies in life sciences innovation. 
|
|
By Ben Adams Otsuka and Lundbeck’s atypical antipsychotic Rexulti has taken the crown away from AbbVie as the largest TV drug ad spender in April, according to the latest data out from real-time ad trackers iSpot.TV. |
By Max Bayer Zenas BioPharma has raised a $200 million series C to fund further clinical development of its lead autoimmune treatment. The company expects four mid-to-late-stage readouts before 2026. |
By Zoey Becker The topical gene therapy has pulled in nearly $100 million during its first three quarters on the U.S. market. Meanwhile, Vyjuvek is currently under review in Europe, and a filing in Japan is planned for later this year. |
By Max Bayer Lykos Therapeutics’ MDMA-assisted therapy is charting yet another first in the psychedelic field: an FDA advisory meeting. |
By Conor Hale Outset Medical has resumed distributing its portable dialysis machine after halting sales last summer, now that it’s obtained a necessary green light from the FDA. |
By Eric Sagonowsky,Fraiser Kansteiner Kenvue’s board of directors on Monday approved a plan to cut 4% of the company’s global workforce. The J&J spinoff employed about 23,000 staffers at the end of last year, so the layoff initiative could affect some 920 workers. |
By Gabrielle Masson Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment, dubbed vanza triple. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. |
|
|---|
|
|
|
Wednesday, May 22, 2024 | 11am ET / 8 am PT Learn GMP regulations in pharmaceutical storage at our upcoming webinar. Discover FDA requirements, including space validation, environmental controls, and risk mitigation. Explore services like aliquoting and cold chain transportation. Register now. 
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
